John Crowley, Amicus Therapeutics discusses drug trial results for Pompe disease

(5:38)

John F. Crowley, Chairman and CEO of Amicus Therapeutics

(29:28)

Cramer's lightning round: Amicus Therapeutics is an ideal spec

(4:1econd)

Amicus Therapeutics

(13:18)

Amicus releases phase 3 results in Pompe disease trial

(1:14)

Amicus Therapeutics FOLD Q3 2024 Earnings Presentation

(54:13)

Amicus Therapeutics

(15:24)

22. An Amicus Presentation with Brian Fox

(16:43)

Amicus Therapeutics | Advancing Therapies for Rare Diseases | The Crowley Family

(3:12)

Congratulations to Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics (2)

(2:56)

Amicus Therapeutics and Cullinan Therapeutics: Analyst Ratings and Insider Trading Insights

(7:24)

Congratulations to Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics (2)

(2:56)

John F. Crowley, Chairman and CEO, Amicus Therapeutics | Mason Public Leadership Lecture

(48:40)

Congratulations to Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics (3)

(9:58)

How Amicus Therapeutics Decides Which Gene Therapy to Focus On

(2:26)

Working at Amgen

(2:22)

16 Years of Jacknjellify! 🎂 (Music Video)

(2:39)

Sanofi – Making Vaccines

(5:27)

CEO of Amicus Provides Update on Their Fabry Disease Program

(3:57)

Amicus Therapeutics

(15:8)